The FDA has approved naldemedine (Symproic) 0.2-mg tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain, Shionogi Inc. and Purdue Pharma L.P. announced.
Naldemedine is a peripherally acting mu-opioid antagonist designed to be taken once daily by adults with OIC. The approval was based on reviewing data from three clinical trials (COMPOSE I, II and III) showing the safety and efficacy of naldemedine for inducing spontaneous bowel movements compared
MARCH 24, 2017